Shares of Amgen Inc. AMGN inched 0.08% higher to $278.32 Tuesday, on what proved to be an all-around mixed trading session ...

Patients with recurrent platinum-sensitive ovarian cancer did just as well with cytoreductive surgery alone as they did with ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

The donation to Rush’s orthopedic department, the largest ever, creates four new endowed positions and programs.

Following a pair of similar deals in January and June, Coherus BioSciences has netted itself a hefty chunk of change for the ...

High-yield bargain opportunities exist for disciplined, value-focused investors. Read more about the two standout stocks I've ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

"This is an exciting time to be joining Tonix as it prepares to receive an FDA decision on its NDA for TNX-102 SL for the ...

Shares of Janux Therapeutics skyrocketed Tuesday on "unprecedented" results for an experimental prostate cancer treatment.

German biotech asks federal judge to reject Amgen’s efforts to narrow scope of a key patent in ongoing dispute | Patent ...

There's a growing number of companies entering the weight loss space, focusing on GLP-1 drugs which can be game changers for ...

Johnson & Johnson JNJ announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients. While one sBLA seeks approval ...